Thermo Fisher Scientific Cash & Equivalents increased by 389.9% to $9.85B in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 145.7%, from $4.01B to $9.85B. Over 5 years (FY 2020 to FY 2025), Cash & Equivalents shows relatively stable performance with a -1.0% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
An increase signals improved liquidity and the ability to fund operations or acquisitions without debt; a decrease may indicate heavy capital expenditure or shareholder returns.
Represents the most liquid assets on the balance sheet, including physical currency and short-term instruments with matu...
Peer tech giants like Alphabet or Apple maintain massive cash reserves to navigate market volatility and fund R&D.
cash_and_equivalents| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $7.04B | $12.05B | $4.49B | $2.78B | $1.91B | $2.93B | $8.54B | $3.50B | $3.15B | $6.17B | $8.10B | $5.52B | $7.10B | $4.67B | $4.01B | $4.17B | $4.60B | $2.01B | $9.85B |
| QoQ Change | — | +71.3% | -62.7% | -38.1% | -31.5% | +54.0% | +191.0% | -59.0% | -9.9% | +95.6% | +31.3% | -31.8% | +28.6% | -34.2% | -14.2% | +4.1% | +10.3% | -56.3% | +389.9% |
| YoY Change | — | — | — | — | -72.9% | -75.6% | +90.1% | +25.9% | +65.5% | +110.2% | -5.2% | +57.7% | +125.1% | -24.3% | -50.5% | -24.4% | -35.1% | -56.9% | +145.7% |
We use cookies for analytics. See our Privacy and Cookie Policy.